Skye Bioscience Appoints New CMO, Director
Ticker: SKYE · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1516551
Sentiment: neutral
Topics: management-change, board-appointment, executive-compensation
TL;DR
Skye Bioscience brings in a new CMO and adds a director to the board.
AI Summary
Skye Bioscience, Inc. announced on October 28, 2024, the appointment of Dr. Robert L. Smith as Chief Medical Officer and the election of Ms. Sarah Chen to its Board of Directors. The company also disclosed compensatory arrangements for its officers, details of which are filed as exhibits.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or leadership focus, potentially impacting its future development and operational plans.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Registrant
- Dr. Robert L. Smith (person) — Appointed Chief Medical Officer
- Ms. Sarah Chen (person) — Elected to Board of Directors
- October 28, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for Skye Bioscience?
Dr. Robert L. Smith has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors at Skye Bioscience?
Ms. Sarah Chen has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 28, 2024.
What other information is disclosed regarding company officers in this filing?
The filing discloses compensatory arrangements for its officers.
In which state was Skye Bioscience, Inc. incorporated?
Skye Bioscience, Inc. was incorporated in Nevada.
Filing Stats: 767 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-10-29 17:25:22
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 SKYE Nasdaq Global Market Indicate
- $610,00 — annual base salary will be increased to $610,00 and Ms. Arsenault's base salary will be
- $450,000 — ault's base salary will be increased to $450,000. In addition, on October 28, 2024, th
Filing Documents
- skye-20241028.htm (8-K) — 32KB
- a241029_skyexnrxgraysoncha.htm (EX-99.1) — 11KB
- 0001516551-24-000093.txt ( ) — 169KB
- skye-20241028.xsd (EX-101.SCH) — 2KB
- skye-20241028_def.xml (EX-101.DEF) — 2KB
- skye-20241028_lab.xml (EX-101.LAB) — 21KB
- skye-20241028_pre.xml (EX-101.PRE) — 12KB
- skye-20241028_htm.xml (XML) — 2KB
01 Other Events
Item 8.01 Other Events. On October 29, 2024, the Company issued a press release announcing the resignation of Mr. Dhillon as the Chairman of the Board and the appointment of Mr. Paul Grayson as the new Chairman of the Board. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 P ress Release dated October 29, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SKYE BIOSCIENCE, INC. Dated: October 29, 2024 /s/ Punit Dhillon Name: Punit Dhillon Title: Chief Executive Officer